Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

EU Gene Therapy Submissions, Approvals Expected To Pick Up In 2021

Jan 04 2021

• By Amanda Micklus

2021 Pink Sheet Perspectives - gene therapy — Biomarin, Krystal Biotech, Orchard Therapeutics expected to submit gene therapies in 2021 for EU review.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

Related Content

Keeping Track: Kite’s Tecartus Is Third CAR-T With US FDA Approval; Submissions Round-Up

Jul 27 2020

BioMarin Pulls EU Hemophilia Gene Therapy Filing, But Is Not Giving Up

Nov 16 2020

Not Such A Sure Thing: FDA Knocks Back BioMarin’s Roctavian

Aug 20 2020

Disappointing End For MolMed’s Zalmoxis Cell Therapy In EU

Oct 11 2019

Fast-Track Loss In EU For Celgene’s CAR-T Cell Therapy

Dec 18 2020

European CHMP Opinions and MAA Updates

Dec 21 2020

Related Companies

Gilead Sciences, Inc.

Orchard Therapeutics Limited

Genetix Biotherapeutics

Bristol Myers Squibb Company

BioMarin Pharmaceutical Inc.

Additional Topics

Europe Gene Therapy Drug Review Regenerative Medicine Regulation Pink Sheet Perspectives BioPharmaceutical

More from Cell & Gene Therapies

More from Advanced Technologies

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window